Sunrise gets vote of confidence from bank
This article was originally published in Clinica
Executive Summary
US refractive surgery company Sunrise Technologies International has announced that its bank has given the company two more months'extension on its credit facility. The company has drastically reduced its costs and has seen its revenues rise rapidly this year, but is facing a cashflow problem. Its working capital diminished to just over $1 million at the end of the first quarter.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.